Is the price fair?
What CAI's price assumes
Caris Life Sciences, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 5.57× revenue.
5.57
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.46%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +38%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
- Price / book
- 8.51
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 8.51
- EV / EBIT2026-Q1
- 42.6
- EV / sales2026-Q1
- 5.08
- Free cash flow, trailing twelve months
- $24M
- Market capitalisation
- $5.22B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.